| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1996PNAS...93.1956H |
| P356 | DOI | 10.1073/PNAS.93.5.1956 |
| P932 | PMC publication ID | 39890 |
| P698 | PubMed publication ID | 8700866 |
| P5875 | ResearchGate publication ID | 14501183 |
| P2093 | author name string | D A Lewis | |
| M J Zigmond | |||
| T G Hastings | |||
| P2860 | cites work | Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures | Q26778382 |
| The crystal structure of dihydrodipicolinate synthase from Escherichia coli at 2.5 A resolution | Q27730365 | ||
| Identification of catechol-protein conjugates in neostriatal slices incubated with [3H]dopamine: impact of ascorbic acid and glutathione | Q72109104 | ||
| Expression and distribution of two isoforms of tyrosine hydroxylase in macaque monkey brain | Q72368126 | ||
| Coordinate end-product inhibition in lysine synthesis in Escherichia coli | Q76427399 | ||
| Purification and characterization of dihydrodipicolinate synthase from wheat suspension cultures | Q83265752 | ||
| Isolation and characterization of dihydrodipicolinate synthase from maize | Q83271459 | ||
| Amino Acid Biosynthesis and its Regulation | Q28300320 | ||
| Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity | Q28325787 | ||
| Aspartate aminotransferase in effective and ineffective alfalfa nodules : cloning of a cDNA and determination of enzyme activity, protein, and mRNA levels | Q33241936 | ||
| Characterization of iron superoxide dismutase cDNAs from plants obtained by genetic complementation in Escherichia coli | Q33927065 | ||
| Maize glutamine synthetase cDNAs: isolation by direct genetic selection in Escherichia coli | Q33954917 | ||
| A soybean gene encoding delta 1-pyrroline-5-carboxylate reductase was isolated by functional complementation in Escherichia coli and is found to be osmoregulated | Q34048055 | ||
| Molecular cloning of wheat dihydrodipicolinate synthase | Q34083506 | ||
| Lysine synthesis and catabolism are coordinately regulated during tobacco seed development | Q35123565 | ||
| Chromosomal location and nucleotide sequence of the Escherichia coli dapA gene | Q36284198 | ||
| Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease | Q36349458 | ||
| Isolation and characterisation of a maize cDNA that complements a 1-acyl sn-glycerol-3-phosphate acyltransferase mutant of Escherichia coli and encodes a protein which has similarities to other acyltransferases | Q36725465 | ||
| Molecular cloning and bacterial expression of cDNA encoding a plant cysteine synthase | Q37177689 | ||
| Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones | Q39615110 | ||
| A cluster of three genes (dapA, orf2, and dapB) of Brevibacterium lactofermentum encodes dihydrodipicolinate synthase, dihydrodipicolinate reductase, and a third polypeptide of unknown function | Q39928252 | ||
| Nucleotide sequence of the dapA gene from Corynebacterium glutamicum | Q40525682 | ||
| Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease | Q41346993 | ||
| Parkinson's disease: a disorder due to nigral glutathione deficiency? | Q41628096 | ||
| Escherichia coli dihydrodipicolinate synthase. Identification of the active site and crystallization | Q42048203 | ||
| The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra | Q42192455 | ||
| Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats | Q42478464 | ||
| Direct genetic selection of a maize cDNA for dihydrodipicolinate synthase in an Escherichia coli dapA- auxotroph | Q42623265 | ||
| Striatal protection induced by lesioning the substantia nigra of rats subjected to focal ischemia | Q44807649 | ||
| Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease | Q44808814 | ||
| Regulation of lysine synthesis in transgenic potato plants expressing a bacterial dihydrodipicolinate synthase in their chloroplasts. | Q45956660 | ||
| In vivo autoxidation of dopamine in guinea pig striatum increases with age. | Q46855135 | ||
| Purification and characterization of dihydrodipicolinate synthase from pea. | Q47917552 | ||
| Partial purification and characterization of lysine-ketoglutarate reductase in normal and opaque-2 maize endosperms | Q47917611 | ||
| Cloning and expression of the soybean DapA gene encoding dihydrodipicolinate synthase | Q48078159 | ||
| Serotonergic afferents to the rat olfactory bulb: I. Origins and laminar specificity of serotonergic inputs in the adult rat. | Q48203800 | ||
| An immunohistochemical characterization of somatostatin-28 and somatostatin-281-12 in monkey prefrontal cortex | Q48341175 | ||
| Nerve terminal damage in cerebral ischemia: protective effect of alpha-methyl-para-tyrosine | Q48460032 | ||
| Glutathione peroxidase activity in Parkinson's disease brain | Q48462475 | ||
| Role of dopamine in the neurotoxic effects of methamphetamine. | Q48486498 | ||
| Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains | Q48789036 | ||
| Homeostatic control of ascorbate concentration in CNS extracellular fluid | Q48859255 | ||
| An improved HPLC-electrochemical detection method for measuring brain levels of 5-S-cysteinyldopamine, 5-S-cysteinyl-3,4-dihydroxyphenylalanine, and 5-S-cysteinyl-3,4-dihydroxyphenylacetic acid | Q49125657 | ||
| Transgenic canola and soybean seeds with increased lysine. | Q54610772 | ||
| Concerted regulation of lysine and threonine synthesis in tobacco plants expressing bacterial feedback-insensitive aspartate kinase and dihydrodipicolinate synthase. | Q54648733 | ||
| Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro | Q67016091 | ||
| A marked rise in 5-S-cysteinyl-dopamine levels in guinea-pig striatum following reserpine treatment | Q69191107 | ||
| Excitotoxicity of NMDA and kainic acid is modulated by nigrostriatal dopaminergic fibres | Q69268468 | ||
| Detection of 5-S-cysteinyldopamine in human brain | Q69805676 | ||
| Catecholamine toxicity in cerebral cortex in dissociated cell culture | Q69923038 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dopamine | Q170304 |
| neurotoxicity | Q3338704 | ||
| P304 | page(s) | 1956-1961 | |
| P577 | publication date | 1996-03-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections | |
| P478 | volume | 93 |
| Q77068438 | 17 beta-estradiol protects lymphocytes against dopamine and iron-induced apoptosis by a genomic-independent mechanism. Implication in Parkinson's disease |
| Q36948238 | 3,4-Methylenedioxy-N-methamphetamine (ecstasy) promotes the survival of fetal dopamine neurons in culture |
| Q37242709 | 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder |
| Q27863413 | A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles. |
| Q34635445 | A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation |
| Q24293727 | A role for alpha-synuclein in the regulation of dopamine biosynthesis |
| Q37450241 | Activation of early signaling transcription factor, NF-kappaB following low-level manganese exposure |
| Q41841066 | Acute and long‐term response of dopamine nigrostriatal synapses to a single, low‐dose episode of 3‐nitropropionic acid‐mediated chemical hypoxia |
| Q28507691 | Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice |
| Q48201689 | Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: relevance to selective neuronal vulnerability |
| Q46687858 | Alpha-Synuclein Fibrils Interact with Dopamine Reducing its Cytotoxicity on PC12 Cells. |
| Q33545484 | Alpha-synuclein overexpression increases dopamine toxicity in BE2-M17 cells |
| Q35750220 | Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons |
| Q40838713 | Angiotensin receptor II is present in dopaminergic cell line of rat substantia nigra and it is down regulated by aminochrome |
| Q42196555 | Antioxidant-Mediated Modulation of Protein Reactivity for 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopamine Metabolite |
| Q44258769 | Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells |
| Q43681031 | Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases |
| Q34289865 | Are dopamine receptor agonists neuroprotective in Parkinson's disease? |
| Q30579594 | Ascorbic acid is neuroprotective against global ischaemia in striatum but not hippocampus: histological and voltammetric data |
| Q51376344 | Assessment of tyrosine hydroxylase immunoreactive innervation in five subregions of the nucleus accumbens shell in rats treated with repeated cocaine. |
| Q26786019 | Bacoside A: Role in Cigarette Smoking Induced Changes in Brain |
| Q44126676 | Behavioral effects of aminochrome and dopachrome injected in the rat substantia nigra. |
| Q52684187 | Bioenergetic and oxidative effects of free 3-nitrotyrosine in culture: selective vulnerability of dopaminergic neurons and increased sensitivity of non-dopaminergic neurons to dopamine oxidation. |
| Q26786253 | Brain Structural Effects of Antipsychotic Treatment in Schizophrenia: A Systematic Review |
| Q46729468 | Brain imaging in methamphetamine-treated mice using a nitroxide contrast agent for EPR imaging of the redox status and a gadolinium contrast agent for MRI observation of blood-brain barrier function |
| Q64122735 | Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis |
| Q42513244 | Brain-derived neurotrophic factor inhibits apoptosis and dopamine-induced free radical production in striatal neurons but does not prevent cell death |
| Q36019780 | Brief mitochondrial inhibition causes lasting changes in motor behavior and corticostriatal synaptic physiology in the Fischer 344 rat. |
| Q64064705 | Buprenorphine and Methadone as Opioid Maintenance Treatments for Heroin-Addicted Patients Induce Oxidative Stress in Blood |
| Q38164648 | Can stress trigger Parkinson's disease? |
| Q36757540 | Canadian Association of Neurosciences Review: the role of dopamine receptor function in neurodegenerative diseases. |
| Q44039908 | Catechol ortho-quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases. |
| Q22242284 | Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine |
| Q44208202 | Catecholamine-induced oligodendrocyte cell death in culture is developmentally regulated and involves free radical generation and differential activation of caspase-3. |
| Q40085533 | Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence |
| Q28583030 | Changes in endoplasmic reticulum stress proteins and aldolase A in cells exposed to dopamine |
| Q35024921 | Characterization of reduced and oxidized dopamine and 3,4-dihydrophenylacetic acid, on brain mitochondrial electron transport chain activities |
| Q33949952 | Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions |
| Q34360660 | Chronic L-dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleus |
| Q42455114 | Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions |
| Q46450404 | Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. |
| Q48162330 | Clorgyline and deprenyl attenuate striatal malonate and 3-nitropropionic acid lesions |
| Q40620645 | Cocaine Causes Apoptotic Death in Rat Mesencephalon and Striatum Primary Cultures |
| Q44396203 | Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons. |
| Q37101326 | Cocaine induces cell death and activates the transcription nuclear factor kappa-B in PC12 cells |
| Q33603762 | Cytotoxic and genotoxic potential of dopamine |
| Q92156112 | DRG2 Deficient Mice Exhibit Impaired Motor Behaviors with Reduced Striatal Dopamine Release |
| Q37262975 | Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems. |
| Q44492929 | Degeneration of the nigrostriatal pathway and induction of motor deficit by tetrahydrobiopterin: an in vivo model relevant to Parkinson's disease. |
| Q41379166 | Detection of Free and Protein-Bound ortho-Quinones by Near-Infrared Fluorescence |
| Q43218756 | Determination of reactive oxygen species associated with the degeneration of dopaminergic neurons during dopamine metabolism. |
| Q35850734 | Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. |
| Q52604904 | Different Mechanisms Between Copper and Iron in Catecholamines-Mediated Oxidative DNA Damage and Disruption of Gene Expression In Vitro |
| Q73370549 | Differential effect of dopamine catabolism and uptake inhibition on dopamine-induced calcium dysregulation and viability loss |
| Q33915570 | Disparity in the temporal appearance of methamphetamine-induced apoptosis and depletion of dopamine terminal markers in the striatum of mice |
| Q40223933 | Divergent mechanisms of paraquat, MPP+, and rotenone toxicity: oxidation of thioredoxin and caspase-3 activation |
| Q34263572 | Does vitamin C deficiency affect cognitive development and function? |
| Q41090449 | Dopamine acting at D1-like, D2-like and α1-adrenergic receptors differentially modulates theta and gamma oscillatory activity in primary motor cortex |
| Q37734563 | Dopamine and glutamate in Huntington's disease: A balancing act. |
| Q44937132 | Dopamine as a potent inducer of cellular glutathione and NAD(P)H:quinone oxidoreductase 1 in PC12 neuronal cells: a potential adaptive mechanism for dopaminergic neuroprotection |
| Q24338423 | Dopamine covalently modifies and functionally inactivates parkin |
| Q46750122 | Dopamine depletion does not protect against acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in vivo. |
| Q38121068 | Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility |
| Q77296667 | Dopamine inactivates tryptophan hydroxylase and forms a redox-cycling quinoprotein: possible endogenous toxin to serotonin neurons |
| Q46305258 | Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration. |
| Q34119168 | Dopamine mercapturate can augment dopaminergic neurodegeneration |
| Q45296860 | Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. |
| Q44529078 | Dopamine neurotoxicity: age-dependent behavioral and histological effects |
| Q40644472 | Dopamine prevents nitration of tyrosine hydroxylase by peroxynitrite and nitrogen dioxide: is nitrotyrosine formation an early step in dopamine neuronal damage? |
| Q30432694 | Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. |
| Q33705939 | Dopamine quinone modifies and decreases the abundance of the mitochondrial selenoprotein glutathione peroxidase 4. |
| Q40906908 | Dopamine stimulates redox-tyrosine kinase signaling and p38 MAPK in activation of astrocytic C6-D2L cells |
| Q40896147 | Dopamine toxicity in neuroblastoma cells: role of glutathione depletion by L-BSO and apoptosis |
| Q34535020 | Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease |
| Q44013447 | Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease |
| Q36002833 | Dopamine-derived quinones affect the structure of the redox sensor DJ-1 through modifications at Cys-106 and Cys-53 |
| Q35839434 | Dopaminergic signaling and striatal neurodegeneration in Huntington's disease |
| Q43818793 | Effect of acute administration of 1,2,3,4-tetrahydroisoquinoline on the levels of glutathione and reactive oxygen species, and on the enzymatic activity of gamma-glutamyl transpeptidase in dopaminergic structures of rat brain |
| Q44496554 | Effect of sulpiride on the amphetamine-induced changes in extracellular dopamine, DOPAC, and hydroxyl radical generation in the rat striatum |
| Q48377173 | Effects of decreased dopamine transporter levels on nigrostriatal neurons and paraquat/maneb toxicity in mice |
| Q43846379 | Effects of sydnocarb and D-amphetamine on the extracellular levels of amino acids in the rat caudate-putamen |
| Q27304699 | Efficient and biologically relevant consensus strategy for Parkinson's disease gene prioritization. |
| Q36585297 | Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein |
| Q34585156 | Emerging therapies in the pharmacological treatment of Parkinson's disease |
| Q64856215 | Endogenous catechol thioethers may be pro-oxidant or antioxidant. |
| Q40390033 | Enhanced toxicity to the catecholamine tyramine in polyglutamine transfected SH-SY5Y cells |
| Q40897573 | Enhancement of dopaminergic neurotoxicity by the mercapturate of dopamine: relevance to Parkinson's disease |
| Q28180502 | Evidence for non-oxidative dopamine cytotoxicity: potent activation of NF-kappa B and lack of protection by anti-oxidants |
| Q37677250 | Fenpropathrin, a Widely Used Pesticide, Causes Dopaminergic Degeneration |
| Q37801855 | Gene therapy: a viable therapeutic strategy for Parkinson's disease? |
| Q34816461 | Glutathione, iron and Parkinson's disease |
| Q34313803 | Human SOD2 modification by dopamine quinones affects enzymatic activity by promoting its aggregation: possible implications for Parkinson's disease |
| Q39064885 | Inactivation of Aconitase by Tetrahydrobiopterin in DArgic Cells: Relevance to PD. |
| Q44129113 | Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity? |
| Q27308109 | Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits. |
| Q44273860 | Induction of GADD45 and GADD153 in neuroblastoma cells by dopamine-induced toxicity. |
| Q40776570 | Induction of alpha-synuclein aggregation by intracellular nitrative insult. |
| Q42727004 | Induction of neuronal damage in guinea pig brain by intratracheal infusion of 2-chloroethyl ethyl sulfide, a mustard gas analog |
| Q37629259 | Involvement of nicotinic receptors in methamphetamine- and MDMA-induced neurotoxicity: pharmacological implications |
| Q48301354 | Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum |
| Q35019852 | JNK inhibition of VMAT2 contributes to rotenone-induced oxidative stress and dopamine neuron death |
| Q44572684 | Kainic acid lesion-induced nigral neuronal death |
| Q42500404 | Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain? |
| Q73226720 | L-DOPA-quinone inactivates tryptophan hydroxylase and converts the enzyme to a redox-cycling quinoprotein |
| Q64875475 | LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease |
| Q73342048 | Lesion of the substantia nigra pars compacta downregulates striatal glutamate receptor subunit mRNA expression |
| Q33770264 | Levodopa in Parkinson's disease: neurotoxicity issue laid to rest? |
| Q34637864 | Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson's disease model |
| Q42008810 | MPP(+)-induced toxicity in the presence of dopamine is mediated by COX-2 through oxidative stress |
| Q48127716 | Malonate-induced generation of reactive oxygen species in rat striatum depends on dopamine release but not on NMDA receptor activation |
| Q43264695 | Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease. |
| Q39199926 | Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism. |
| Q49499665 | Metabolism of Dopamine in Nucleus Accumbens Astrocytes Is Preserved in Aged Mice Exposed to MPTP. |
| Q33799373 | Methamphetamine abuse, HIV infection, and neurotoxicity. |
| Q57204867 | Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment |
| Q74340381 | Methamphetamine toxicity is attenuated in mice that overexpress human manganese superoxide dismutase |
| Q33961999 | Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. |
| Q37631968 | Mic60/mitofilin overexpression alters mitochondrial dynamics and attenuates vulnerability of dopaminergic cells to dopamine and rotenone |
| Q43808667 | Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine |
| Q30539763 | Microtubule alterations occur early in experimental parkinsonism and the microtubule stabilizer epothilone D is neuroprotective |
| Q48543313 | Mitochondrial DNA deletions/rearrangements in parkinson disease and related neurodegenerative disorders |
| Q55081064 | Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson's Disease and Huntington's Disease. |
| Q36590693 | Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism |
| Q37776087 | Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease |
| Q31962096 | Molecular cloning, localization and characterization of a 40-kDa catecholamine-regulated protein |
| Q43857842 | Muscarinic receptor subtype determines vulnerability to oxidative stress in COS-7 cells |
| Q33904302 | Na(+)/H(+) exchanger inhibition modifies dopamine neurotransmission during normal and metabolic stress conditions. |
| Q33934225 | Neuronal cell death in Huntington's disease: a potential role for dopamine |
| Q51414564 | Neurotoxic relationship between dopamine and iron in the striatal dopaminergic nerve terminals. |
| Q36971051 | New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals |
| Q35746663 | Nitrotyrosine as a marker for peroxynitrite-induced neurotoxicity: the beginning or the end of the end of dopamine neurons? |
| Q36607332 | Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation |
| Q33817921 | Oxidation and nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder and schizophrenia |
| Q35128313 | Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone. |
| Q44028767 | Oxidation of DOPAC by nitric oxide: effect of superoxide dismutase |
| Q37509229 | Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle |
| Q46252606 | Oxidative stress and cellular pathologies in Parkinson's disease. |
| Q35047296 | Oxidative stress and nitration in neurodegeneration: cause, effect, or association? |
| Q33738259 | Oxidative stress in early stage Bipolar Disorder and the association with response to lithium |
| Q28540914 | P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models |
| Q34597817 | Parkin degrades estrogen-related receptors to limit the expression of monoamine oxidases |
| Q40545020 | Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis |
| Q35786982 | Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons |
| Q74708499 | Parkinson's: another look |
| Q41395526 | Passiflora cincinnata Extract Delays the Development of Motor Signs and Prevents Dopaminergic Loss in a Mice Model of Parkinson's Disease |
| Q34520091 | Patterns of methamphetamine abuse and their consequences |
| Q36584927 | Perinatal heptachlor exposure increases expression of presynaptic dopaminergic markers in mouse striatum. |
| Q48491745 | Phencyclidine and corticosteroids induce apoptosis of a subpopulation of striatal neurons: a neural substrate for psychosis? |
| Q42468654 | Phencyclidine induces D-1 dopamine receptor mediated Fos-like immunoreactivity in discretely localised populations of striatopallidal and striatoentopeduncular neurons in the rat. |
| Q35889761 | Polymorphism in the Vesicular Monoamine Transporter 2 Gene Decreases the Risk of Parkinson's Disease in Han Chinese Men. |
| Q37583405 | Polymorphism of the COMT, MAO, DAT, NET and 5-HTT Genes, and Biogenic Amines in Parkinson's Disease |
| Q61809108 | Potential Role of Mic60/Mitofilin in Parkinson's Disease |
| Q46566287 | Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro |
| Q30582194 | Prefrontal cortical and striatal transcriptional responses to the reinforcing effect of repeated methylphenidate treatment in the spontaneously hypertensive rat, animal model of attention-deficit/hyperactivity disorder (ADHD). |
| Q90733951 | Preventive and Therapeutic Potential of Vitamin C in Mental Disorders |
| Q47796642 | Production of melanin pigments by cytochrome c/H2O2 system. |
| Q37406074 | Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons |
| Q40073295 | Protective effects of metallothionein against dopamine quinone-induced dopaminergic neurotoxicity |
| Q37269603 | Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. |
| Q37381903 | Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells |
| Q37918059 | Proteostasis and movement disorders: Parkinson's disease and amyotrophic lateral sclerosis |
| Q46527836 | Quinone and oxyradical scavenging properties of N-acetylcysteine prevent dopamine mediated inhibition of Na+, K+-ATPase and mitochondrial electron transport chain activity in rat brain: implications in the neuroprotective therapy of Parkinson's dise |
| Q36856168 | Quinone reductase 2 is a catechol quinone reductase |
| Q49016618 | Quinoprotein adducts accumulate in the substantia nigra of aged rats and correlate with dopamine-induced toxicity in SH-SY5Y cells |
| Q48336471 | Rat striatal levels of the antioxidant glutathione are decreased following binge administration of methamphetamine. |
| Q42840855 | Reactive oxygen species generation by the ethylene-bis-dithiocarbamate (EBDC) fungicide mancozeb and its contribution to neuronal toxicity in mesencephalic cells |
| Q39101971 | Reactive oxygen species mediate dopamine-induced signaling in renal proximal tubule cells |
| Q74014790 | Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss |
| Q88316783 | Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities |
| Q38688126 | Redox Signaling in Neurotransmission and Cognition During Aging |
| Q44348330 | Reduced striatal dopamine transporter density associated with working memory deficits in opioid-dependent male subjects: a SPECT study |
| Q36691830 | Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration |
| Q28237641 | Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration |
| Q40914289 | Regulation of heme oxygenase-1 expression by dopamine in cultured C6 glioma and primary astrocytes |
| Q36513557 | Review of apoptosis vs. necrosis of substantia nigra pars compacta in Parkinson's disease |
| Q28374491 | Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures |
| Q43509401 | Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine |
| Q40656558 | Role of reactive oxygen species in extracellular signal-regulated protein kinase phosphorylation and 6-hydroxydopamine cytotoxicity. |
| Q36938969 | S-Glutathionylation and Redox Protein Signaling in Drug Addiction |
| Q46642857 | Selective vulnerability of dopaminergic neurons to microtubule depolymerization |
| Q48449952 | Spatial learning and memory deficits induced by dopamine administration with decreased glutathione |
| Q42504689 | Stress-induced increase in extracellular dopamine in striatum: role of glutamatergic action via N-methyl-D-aspartate receptors in substantia nigra |
| Q24339442 | Structure and Function of Parkin, PINK1, and DJ-1, the Three Musketeers of Neuroprotection |
| Q35978877 | Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. |
| Q28365464 | Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease |
| Q34459294 | Synergism between methamphetamine and the neuropeptide substance P on the production of nitric oxide in the striatum of mice |
| Q50090415 | Synuclein and dopamine: the Bonnie and Clyde of Parkinson's disease |
| Q57167598 | Targeting redox regulation to treat substance use disorder using N-acetylcysteine |
| Q38760523 | The Molecular Chaperone Hsc70 Interacts with Tyrosine Hydroxylase to Regulate Enzyme Activity and Synaptic Vesicle Localization. |
| Q36525175 | The application of NMR-based metabonomics in neurological disorders |
| Q48164714 | The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models |
| Q86630502 | The effects of aging and oxidative stress on psychomotor and cognitive behavior |
| Q31744197 | The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. |
| Q44722696 | The possible role of one-electron reduction of aminochrome in the neurodegenerative process of the dopaminergic system. |
| Q38031289 | The relationship between oxidative stress and post-translational modification of the dopamine transporter in bipolar disorder |
| Q34679230 | The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases |
| Q31804333 | The reverse transport of DA, what physiological significance? |
| Q37646362 | The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease |
| Q40791398 | The transcription factor E2F1 promotes dopamine-evoked neuronal apoptosis by a mechanism independent of transcriptional activation |
| Q64785696 | The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration |
| Q38176494 | The vesicular monoamine transporter 2: an underexplored pharmacological target |
| Q89973008 | Thiol-mediated and catecholamine-enhanced multimerization of a cerebrovascular disease enriched fragment of NOTCH3 |
| Q36326535 | Thiol-redox signaling, dopaminergic cell death, and Parkinson's disease |
| Q28587110 | Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats |
| Q44574098 | Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat. |
| Q34917732 | Toxic effects of dopamine metabolism in Parkinson's disease. |
| Q73593746 | Toxicity of dopamine and dopaminochrome on cultured cells |
| Q24811691 | Understanding the human health effects of chemical mixtures |
| Q46815723 | Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice |
| Q28385737 | Vesicular integrity in Parkinson's disease |
| Q48130399 | Vulnerability of the mesencephalic dopaminergic neurons of the human neonate to prolonged perinatal hypoxia: an immunohistochemical study of tyrosine hydroxylase expression in autopsy material |
| Q37731356 | Zinc-metallothionein: a potential mediator of antioxidant defence mechanisms in response to dopamine-induced stress |
| Q33876975 | skn-1-Dependent and -independent regulation of aip-1 expression following metabolic stress in Caenorhabditis elegans |
Search more.